Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Neuronetics Earnings Call: Key Takeaways

Neuronetics reported 9% revenue growth driven by Greenbrook clinics while pivoting Neurostar to a capital-purchase model to address broader market demand and improve profitability.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthGreenbrook up 17% to $26.9M; Neurostar capital up double-digits; sessions down double-digits.
Mgmt ConfidenceHigh confidence in new commercial models and Greenbrook operational discipline improvements.
Demand VisibilityUtilization up 10% in active accounts; 40% unused capacity at Greenbrook.
Margin TrendsGross margin 51.1% vs 46.6% LY; FY2026 guidance raised to 48%-50%.
Op. LeverageClinics carry fixed costs; increasing occupancy from 60% drives significant profitability.
Pricing PowerImproved reimbursement rates through effective payer contracting for TMS and Spravado.
Vol vs PriceGrowth driven by Greenbrook volume and improved revenue cycle management pricing.
Segment GrowthGreenbrook clinics outperforming; Neurostar transitioning from recurring sessions to capital sales.
New ClientsExpanded Neurostar pilot to broader rollout; collaboration with A&T Neuro announced.
Capex & DebtRaised $7.6M via ATM; cash balance $25M; reduced cash burn significantly.
RegulatoryMonitoring Compass Pathways' psilocybin regulatory path for future Greenbrook delivery integration.
CommentaryShifting from high-touch session model to flexible capital and a-la-carte support.
New LaunchesIntroduced Neurostar lease-finance options and a-la-carte clinical support services.

Growth

Total revenue $41.6M (up 9%); Greenbrook revenue $26.9M (up 17%); Neurostar revenue $14.7M (down 2.7%).

Outlook

Narrowed FY2026 revenue guidance to $160M-$164M; targeting positive cash flow in second half 2026.

Risks

Neurostar session revenue fell double-digits; management pivoted to holistic reporting, potentially obscuring specific segment declines.

Source

The company's earnings call, NASDAQ: STIM, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Neuronetics, Inc.: key numbers

Share price
$1.25Close, Nov 16
Market cap
$97.2M
Shares outstanding
77.73MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Neuronetics, Inc.

All →
9:44 PM ET Form 4
Insider Buying

Neuronetics Insider Jorey Chernett Buys $79.6K of Stock

Jorey Chernett bought 40,000 shares of Neuronetics, Inc. at $1.99 a share, worth $79.6K in total on Nov 9, 2026. Shares held after the trade: 10,306,225 (+0.4%).

Value
$79.6K
Shares
40,000
Price
$1.99
Holding change
+0.4%
Trade date
Nov 9, 2026
9:44 PM ET Form 4
Insider Selling

Neuronetics Insider Jorey Chernett Sells $4.48M of Stock

Jorey Chernett sold 3,335,411 shares of Neuronetics, Inc. at $1.15 to $2.39 a share (average $1.34) in 5 transactions, worth $4.48M in total between Nov 6, 2026 and Nov 13, 2026. Shares held after the trade: 7,325,577 (-23.0%).

Value
$4.48M
Shares
3,335,411
Average price
$1.34
Holding change
-23.0%
Trade date
Nov 6, 2026 to Nov 13, 2026
4:10 PM ET 8-K/A
Capital Raise

Neuronetics Capital Raise of $30M

Neuronetics, Inc. entered into an underwriting agreement to sell 18,750,000 shares of common stock at a public offering price of $1.60 per share. The company also granted underwriters a 30-day option to purchase an additional 2,812,500 shares, bringing the total potential gross proceeds to approximately $34.5 million. Net proceeds will be used to repay a portion of outstanding term loans under its Perceptive Credit Facility and for general corporate purposes.

Value
$30M
Counterparty
William Blair & Company, L.L.C.
8:34 AM ET 8-K
Capital Raise

Neuronetics Capital Raise of $30M

Neuronetics, Inc. entered into an underwriting agreement to sell 18,750,000 shares of common stock at $1.60 per share, with an additional 2,812,500 shares available via an underwriters' option. The company expects to raise approximately $30 million in gross proceeds ($27.7 million net) to repay debt under its Perceptive Credit Facility and for general corporate purposes.

Value
$30M
Counterparty
William Blair & Company, L.L.C.
4:10 PM ET 8-K
Loan & Debt

Neuronetics Debt Financing Update with Perceptive Credit Holdings IV, LP

Neuronetics entered into Amendment No. 6 to its existing Credit Agreement with Perceptive Credit Holdings IV, LP to modify certain revenue covenants. The amendment is subject to an optional prepayment of at least $15 million plus interest and fees, and will automatically terminate if conditions are not met by November 30, 2026.

Counterparty
Perceptive Credit Holdings IV, LP
8:01 AM ET 10-Q
Financial Results ▶ Call

Neuronetics Q3 2026 Results: Net Loss of $1.69M, Loss Narrows

Neuronetics, Inc. reported total revenues of $41.96 million for the quarter ended September 30, 2026, a 12.5% increase over the prior year, driven primarily by growth in the Greenbrook segment. The company achieved a quarterly income from operations of $0.54 million compared to a loss of $7.32 million in the prior year, though it maintained a net loss of $1.56 million for the period.

Key figure
Net loss $1.69M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.